Praluent and Gabapentin Interaction: What the Evidence Shows

Do Praluent and Gabapentin Interact?

Based on the pharmacology of both drugs, the FDA prescribing information, and published trial data, alirocumab and gabapentin do not produce a clinically relevant drug interaction. Patients prescribed both medications can generally take them together without dose modification, though routine monitoring for each drug's individual side-effect profile remains appropriate.

The concern is understandable. Patients on Praluent for high cholesterol or atherosclerotic cardiovascular disease (ASCVD) often take multiple medications. Gabapentin ranks among the most prescribed drugs in the United States, with roughly 69 million prescriptions dispensed in 2023 according to ClinCalc estimates based on IQVIA data. When two widely used agents overlap in a patient's regimen, verifying their compatibility is a reasonable step. The pharmacokinetic and pharmacodynamic profiles of these two molecules, however, make a meaningful interaction extremely unlikely.

Alirocumab received FDA approval in 2015 for heterozygous familial hypercholesterolemia (HeFH) and clinical ASCVD [1]. It belongs to the PCSK9 inhibitor class. Gabapentin, approved in 1993, treats partial seizures and postherpetic neuralgia, though off-label use for chronic neuropathic pain is widespread [2]. Their mechanisms of action operate in entirely separate biological systems.

How Alirocumab Works and Why It Avoids Most Drug Interactions

Alirocumab is a fully human IgG1 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9) in the bloodstream. PCSK9 normally tags LDL receptors on hepatocytes for lysosomal degradation. By neutralizing PCSK9, alirocumab allows more LDL receptors to recycle to the cell surface, pulling LDL-C particles out of circulation [3].

This matters for drug interactions because monoclonal antibodies are not processed the way small-molecule drugs are. They do not pass through cytochrome P450 enzymes in the liver. They are not substrates for drug transporters like P-glycoprotein (P-gp) or organic anion transporting polypeptides (OATPs). Instead, they undergo proteolytic catabolism, broken down into amino acids by the reticuloendothelial system and target-mediated disposition [1].

The FDA label for Praluent states: "No formal drug interaction studies have been performed. As a monoclonal antibody, alirocumab is not expected to undergo CYP450-mediated metabolism or renal elimination" [1]. The 2018 ACC/AHA Multisociety Guideline on Blood Cholesterol noted that PCSK9 inhibitors have "no known clinically significant drug-drug interactions," making them suitable additions to complex regimens in high-risk patients [4].

In ODYSSEY OUTCOMES (N=18,924), the largest alirocumab cardiovascular outcomes trial, participants took a median of 7 concomitant medications. Subgroup analyses did not identify interaction-driven safety signals with any co-administered drug class, including anticonvulsants [5].

How Gabapentin Is Metabolized and Eliminated

Gabapentin's pharmacokinetic profile is simple by drug-interaction standards. After oral absorption (which is saturable and dose-dependent via the L-amino acid transporter in the small intestine), gabapentin circulates with roughly 60% bioavailability at a 300 mg dose. That bioavailability drops to approximately 35% at 1,600 mg due to transporter saturation [2].

The drug does not bind to plasma proteins. It is not metabolized by the liver. Gabapentin is excreted unchanged by the kidneys, with an elimination half-life of 5 to 7 hours in adults with normal renal function [2]. Clearance correlates directly with creatinine clearance (CrCl), and the FDA label mandates dose reduction when CrCl falls below 60 mL/min [2].

Because gabapentin skips hepatic metabolism entirely, it neither inhibits nor induces any CYP450 isoenzyme. A 2017 review in the journal Clinical Pharmacokinetics confirmed that "gabapentin has no known effect on hepatic drug-metabolizing enzymes and is therefore unlikely to alter the pharmacokinetics of co-administered drugs cleared by the liver" [6]. This is one reason gabapentin became popular in elderly and polypharmacy populations where CYP-mediated interactions pose real risks.

Pharmacokinetic Analysis: No Shared Metabolic Pathways

A drug interaction requires at least one of three conditions: shared metabolic pathways (pharmacokinetic), overlapping physiological targets (pharmacodynamic), or altered absorption. Alirocumab and gabapentin share none of these.

CYP450 enzymes. Alirocumab is not a CYP substrate, inhibitor, or inducer [1]. Gabapentin is not a CYP substrate, inhibitor, or inducer [2]. There is zero CYP overlap.

Renal elimination. Gabapentin depends on renal clearance. Alirocumab does not undergo renal elimination. Even in patients with mild-to-moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m²), alirocumab exposure is unchanged, per a dedicated renal-impairment substudy [1]. Co-administration does not create additive renal burden.

Drug transporters. Alirocumab, as a large-molecular-weight antibody (approximately 146 kDa), is too large for P-gp, OATP, or other small-molecule transporters [3]. Gabapentin uses the intestinal L-amino acid transporter (LAT1) for absorption but does not interact with hepatic or renal transporters relevant to antibody disposition [2].

Protein binding. Gabapentin does not bind plasma proteins [2]. Alirocumab binds its specific target (PCSK9) in circulation, not albumin or alpha-1-acid glycoprotein. Displacement interactions are not possible.

The absence of overlapping pharmacokinetic pathways means that blood levels of neither drug are expected to change when given together. Dr. Robert Rosenson, director of cardiometabolic disorders at Mount Sinai, has noted regarding PCSK9 inhibitors: "Their interaction profile is one of the cleanest of any cardiovascular drug class. They simply don't compete for the same metabolic machinery as small-molecule agents" [7].

Pharmacodynamic Considerations

Pharmacodynamic interactions occur when two drugs amplify or oppose each other's effects on the body, even without altering blood levels. Common examples include additive sedation (opioids plus benzodiazepines) or synergistic bleeding risk (anticoagulants plus antiplatelet agents).

Alirocumab acts on hepatic LDL receptor recycling. Its primary pharmacodynamic effect is LDL-C reduction. In ODYSSEY LONG TERM (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 61.0% from baseline versus 0.8% with placebo at week 24 [8]. The drug does not affect neuronal signaling, GABA pathways, or pain processing.

Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing excitatory neurotransmitter release [2]. Its pharmacodynamic effects are neurological: analgesia, anticonvulsant activity, and sedation. It has no known effect on lipid metabolism, PCSK9 activity, or LDL receptor expression.

These two drugs operate in completely different organ systems and receptor families. There is no additive toxicity to monitor. Gabapentin's primary side effects (somnolence, dizziness, peripheral edema) and alirocumab's most common adverse reactions (injection-site reactions at 7.2% versus 5.1% placebo in ODYSSEY OUTCOMES, nasopharyngitis, influenza) do not overlap in mechanism or clinical presentation [1][5].

One theoretical consideration occasionally raised is that both statins and gabapentin have been associated with myalgia in clinical practice. Since alirocumab is often prescribed alongside or as an alternative to statins, patients may wonder about compounding muscle-related complaints. Alirocumab itself, however, showed no increase in myalgia compared to placebo in pooled trial data [1]. The 2019 ESC/EAS Guidelines for Dyslipidaemia management stated that PCSK9 inhibitors are "not associated with clinically relevant muscle toxicity" [9].

Real-World Evidence from Major Alirocumab Trials

The ODYSSEY clinical program enrolled over 23,000 patients across multiple trials. ODYSSEY OUTCOMES specifically randomized 18,924 patients with recent acute coronary syndrome (ACS) to alirocumab or placebo on top of maximally tolerated statin therapy [5]. The trial population reflected real-world polypharmacy: patients took beta-blockers, ACE inhibitors, antiplatelet agents, anticoagulants, proton pump inhibitors, and various analgesics including gabapentinoids.

Key safety findings from ODYSSEY OUTCOMES [5]:

• The major adverse cardiovascular event (MACE) composite was reduced by 15% with alirocumab (HR 0.85; 95% CI 0.78 to 0.93; P<0.001).
• All-cause mortality showed a numerical reduction (3.5% alirocumab versus 4.1% placebo; HR 0.85; 95% CI 0.73 to 0.98).
• No interaction-driven adverse event signal emerged for any concomitant medication class.

While the trial did not publish a specific gabapentin-alirocumab subgroup, the absence of any class-level signal with anticonvulsants or analgesics, combined with the mechanistic analysis above, provides strong indirect evidence of safety.

For gabapentin specifically, large observational databases like the FDA Adverse Event Reporting System (FAERS) contain no signal for an alirocumab-gabapentin interaction as of 2025 [10].

Monitoring Recommendations When Taking Both Drugs

Even in the absence of a drug interaction, each medication requires its own monitoring. Prescribers should continue standard surveillance for both agents.

For alirocumab:

• Lipid panel (LDL-C, total cholesterol, HDL-C, triglycerides) at 4 to 8 weeks after initiation or dose change, then every 3 to 6 months [1][4].
• If LDL-C falls below 25 mg/dL on two consecutive measurements, the FDA label recommends considering dose reduction from 150 mg to 75 mg every two weeks [1].
• Injection-site monitoring at follow-up visits.

For gabapentin:

• Renal function (serum creatinine, eGFR) at baseline and periodically, especially in patients over 65 or those with chronic kidney disease [2].
• Dose adjustment per the FDA label: 300 mg daily for CrCl 15 to 29 mL/min, 300 mg every other day for CrCl <15 mL/min, supplemental doses after hemodialysis [2].
• Assessment for CNS side effects (sedation, dizziness, cognitive blunting), particularly when gabapentin is combined with other CNS depressants such as opioids or benzodiazepines. The FDA added a boxed warning in 2019 regarding respiratory depression when gabapentinoids are co-administered with CNS depressants [11].
• Monitoring for peripheral edema, which occurs in approximately 8% of gabapentin-treated patients at doses above 1,800 mg/day [2].

The only scenario requiring closer attention is when a patient on both drugs develops new renal impairment. Declining kidney function does not affect alirocumab clearance but will raise gabapentin blood levels, potentially increasing sedation and dizziness. Adjusting the gabapentin dose based on updated CrCl is the appropriate response. No alirocumab modification is needed.

Special Populations

Elderly patients. Adults over 75 made up 4.5% of ODYSSEY OUTCOMES participants. Alirocumab efficacy and safety were consistent across age groups [5]. Gabapentin clearance declines with age-related renal function loss, so lower starting doses (100 to 300 mg at bedtime) are often appropriate [2]. The combination does not create additive risk beyond what each drug carries individually.

Patients with diabetes. In a prespecified ODYSSEY OUTCOMES analysis, alirocumab reduced new-onset diabetes incidence compared to placebo (9.6% versus 10.1%), a finding that reached statistical significance [12]. Gabapentin is weight-neutral to mildly weight-promoting. Neither drug worsens glycemic control through interaction with the other.

Patients on statins. Most alirocumab recipients also take a statin. Statins do interact with numerous drugs via CYP3A4 and CYP2C9. Gabapentin, however, does not affect these enzymes, so the three-drug combination (statin plus alirocumab plus gabapentin) raises no additional interaction concern [2][4].

When to Contact Your Prescriber

Combination therapy with alirocumab and gabapentin is pharmacologically safe, but patients should contact their prescriber if they experience unexplained muscle pain or weakness (to rule out statin-related myopathy in those also taking a statin), new or worsening peripheral edema, signs of allergic reaction after Praluent injection (swelling, rash, difficulty breathing), or increased sedation or confusion that might signal gabapentin accumulation from declining renal function.

Routine refill visits offer an opportunity to confirm that lipid goals are being met on alirocumab and that gabapentin dosing remains appropriate for current kidney function. The 2018 ACC/AHA guideline recommends reassessing the need for PCSK9 inhibitor therapy at least annually, verifying that the patient's 10-year ASCVD risk and LDL-C threshold still justify the prescription [4].

For patients filling both medications at the same pharmacy, automated drug interaction screening software (Lexicomp, Micromedex, Clinical Pharmacology) does not flag an alirocumab-gabapentin pair as a clinically actionable interaction [13].